Holen Sie sich die Stockscreener-App
2.325
1.30%
-0.015
Schlusskurs vom Vortag:
$2.31
Offen:
$2.26
24-Stunden-Volumen:
359
Relative Volume:
0.03
Marktkapitalisierung:
$4.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.77M
KGV:
-0.8786
EPS:
-2.6464
Netto-Cashflow:
$-2.69M
1W Leistung:
-8.06%
1M Leistung:
+7.04%
6M Leistung:
-0.85%
1J Leistung:
-45.71%
1-Tages-Spanne:
$2.26
$2.26
1-Wochen-Bereich:
$2.13
$2.45
52-Wochen-Spanne:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Firmenname
Xortx Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare XRTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.26 | 4.14M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
522.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.02 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.69 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc Aktie (XRTX) Neueste Nachrichten
Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView
Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages Investor Relations Program - markets.businessinsider.com
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - TipRanks
XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView
XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - Kalkine Media
Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView
Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView
Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - AD HOC NEWS
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - Stock Titan
XORTX Announces Termination and Postponement of Investor Relations Program - Moomoo
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics (TSXV:XRTX) Shares Jump 10.8% in a Volatile Session - kalkine.ca
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks
Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XORTX Therapeutics (XRTX) Advances 5.28% as Shares Test Resistance at $2.38Institutional Sentiment - vinanet.vn
XORTX (XRTX) Q1 2024 Earnings: Loss of -$1.24 per Share Misses Consensus by 372.2%Earnings Revision Upgrade - vinanet.vn
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail
XORTX Therapeutics (XRTX) Edges Higher at $2.21 as Shares Hold Mid-Range PositionLong Term Entry Picks - dars.gov.et
Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan
XORTX Therapeutics (XRTX) Climbs 4.92% as Shares Approach Key Resistance at $2.23Fundamentals - dars.gov.et
XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com
XORTX Director Anthony Giovinazzo Steps Down for Personal Reasons - Stock Titan
XRTX Q1 2024 Earnings: Larger-Than-Expected Loss Highlights Developmental Stage ChallengesProfitability Analysis - vinanet.vn
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks
XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan
XORTX Appoints New Director - GlobeNewswire
XORTX Therapeutics, Inc. Revenue Breakdown – TSXV:XRTX - TradingView
Vectus Biosystems Appoints Dr Tara Speranza as CEO and CTO, Raises $791,000 to Accelerate VB0004 Clinical Development - Kalkine
Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.025|Chg%:-0.090 - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.015|Chg%:-0.010 - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
Finanzdaten der Xortx Therapeutics Inc-Aktie (XRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):